Cargando…
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
BACKGROUND: This study aimed to determine whether single nucleotide polymorphisms (SNPs) in genes involved in DNA repair or metabolism of taxanes or platinum could predict toxicity or response to first-line chemotherapy in ovarian cancer. METHODS: Twenty-six selected SNPs in 18 genes were genotyped...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359565/ https://www.ncbi.nlm.nih.gov/pubmed/25881102 http://dx.doi.org/10.1186/s40360-015-0001-5 |
_version_ | 1782361433157140480 |
---|---|
author | Lambrechts, Sandrina Lambrechts, Diether Despierre, Evelyn Van Nieuwenhuysen, Els Smeets, Dominiek Debruyne, Philip R Renard, Vincent Vroman, Philippe Luyten, Daisy Neven, Patrick Amant, Frédéric Leunen, Karin Vergote, Ignace |
author_facet | Lambrechts, Sandrina Lambrechts, Diether Despierre, Evelyn Van Nieuwenhuysen, Els Smeets, Dominiek Debruyne, Philip R Renard, Vincent Vroman, Philippe Luyten, Daisy Neven, Patrick Amant, Frédéric Leunen, Karin Vergote, Ignace |
author_sort | Lambrechts, Sandrina |
collection | PubMed |
description | BACKGROUND: This study aimed to determine whether single nucleotide polymorphisms (SNPs) in genes involved in DNA repair or metabolism of taxanes or platinum could predict toxicity or response to first-line chemotherapy in ovarian cancer. METHODS: Twenty-six selected SNPs in 18 genes were genotyped in 322 patients treated with first-line paclitaxel-carboplatin or carboplatin mono-therapy. Genotypes were correlated with toxicity events (anemia, neutropenia, thrombocytopenia, febrile neutropenia, neurotoxicity), use of growth factors and survival. RESULTS: The risk of anemia was increased for variant alleles of rs1128503 (ABCB1, C > T; p = 0.023, OR = 1.71, 95% CI = 1.07-2.71), rs363717 (ABCA1, A > G; p = 0.002, OR = 2.08, 95% CI = 1.32-3.27) and rs11615 (ERCC1, T > C; p = 0.031, OR = 1.61, 95% CI = 1.04-2.50), while it was decreased for variant alleles of rs12762549 (ABCC2, C > G; p = 0.004, OR = 0.51, 95% CI = 0.33-0.81). Likewise, increased risk of thrombocytopenia was associated with rs4986910 (CYP3A4, T > C; p = 0.025, OR = 4.99, 95% CI = 1.22-20.31). No significant correlations were found for neurotoxicity. Variant alleles of rs2073337 (ABCC2, A > G; p = 0.039, OR = 0.60, 95% CI = 0.37-0.98), rs1695 (ABCC1, A > G; p = 0.017, OR = 0.55, 95% CI 0.33-0.90) and rs1799793 (ERCC2, G > A; p = 0.042, OR = 0.63, 95% CI 0.41-0.98) associated with the use of colony stimulating factors (CSF), while rs2074087 (ABCC1, G > C; p = 0.011, OR = 2.09, 95% CI 1.18-3.68) correlated with use of erythropoiesis stimulating agents (ESAs). Homozygous carriers of the rs1799793 (ERCC2, G > A) G-allele had a prolonged platinum-free interval (p = 0.016). CONCLUSIONS: Our data reveal significant correlations between genetic variants of transport, hepatic metabolism, platinum related detoxification or DNA damage repair and toxicity or outcome in ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0001-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4359565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43595652015-03-15 Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer Lambrechts, Sandrina Lambrechts, Diether Despierre, Evelyn Van Nieuwenhuysen, Els Smeets, Dominiek Debruyne, Philip R Renard, Vincent Vroman, Philippe Luyten, Daisy Neven, Patrick Amant, Frédéric Leunen, Karin Vergote, Ignace BMC Pharmacol Toxicol Research Article BACKGROUND: This study aimed to determine whether single nucleotide polymorphisms (SNPs) in genes involved in DNA repair or metabolism of taxanes or platinum could predict toxicity or response to first-line chemotherapy in ovarian cancer. METHODS: Twenty-six selected SNPs in 18 genes were genotyped in 322 patients treated with first-line paclitaxel-carboplatin or carboplatin mono-therapy. Genotypes were correlated with toxicity events (anemia, neutropenia, thrombocytopenia, febrile neutropenia, neurotoxicity), use of growth factors and survival. RESULTS: The risk of anemia was increased for variant alleles of rs1128503 (ABCB1, C > T; p = 0.023, OR = 1.71, 95% CI = 1.07-2.71), rs363717 (ABCA1, A > G; p = 0.002, OR = 2.08, 95% CI = 1.32-3.27) and rs11615 (ERCC1, T > C; p = 0.031, OR = 1.61, 95% CI = 1.04-2.50), while it was decreased for variant alleles of rs12762549 (ABCC2, C > G; p = 0.004, OR = 0.51, 95% CI = 0.33-0.81). Likewise, increased risk of thrombocytopenia was associated with rs4986910 (CYP3A4, T > C; p = 0.025, OR = 4.99, 95% CI = 1.22-20.31). No significant correlations were found for neurotoxicity. Variant alleles of rs2073337 (ABCC2, A > G; p = 0.039, OR = 0.60, 95% CI = 0.37-0.98), rs1695 (ABCC1, A > G; p = 0.017, OR = 0.55, 95% CI 0.33-0.90) and rs1799793 (ERCC2, G > A; p = 0.042, OR = 0.63, 95% CI 0.41-0.98) associated with the use of colony stimulating factors (CSF), while rs2074087 (ABCC1, G > C; p = 0.011, OR = 2.09, 95% CI 1.18-3.68) correlated with use of erythropoiesis stimulating agents (ESAs). Homozygous carriers of the rs1799793 (ERCC2, G > A) G-allele had a prolonged platinum-free interval (p = 0.016). CONCLUSIONS: Our data reveal significant correlations between genetic variants of transport, hepatic metabolism, platinum related detoxification or DNA damage repair and toxicity or outcome in ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0001-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-27 /pmc/articles/PMC4359565/ /pubmed/25881102 http://dx.doi.org/10.1186/s40360-015-0001-5 Text en © Lambrechts et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lambrechts, Sandrina Lambrechts, Diether Despierre, Evelyn Van Nieuwenhuysen, Els Smeets, Dominiek Debruyne, Philip R Renard, Vincent Vroman, Philippe Luyten, Daisy Neven, Patrick Amant, Frédéric Leunen, Karin Vergote, Ignace Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
title | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
title_full | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
title_fullStr | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
title_full_unstemmed | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
title_short | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
title_sort | genetic variability in drug transport, metabolism or dna repair affecting toxicity of chemotherapy in ovarian cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359565/ https://www.ncbi.nlm.nih.gov/pubmed/25881102 http://dx.doi.org/10.1186/s40360-015-0001-5 |
work_keys_str_mv | AT lambrechtssandrina geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT lambrechtsdiether geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT despierreevelyn geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT vannieuwenhuysenels geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT smeetsdominiek geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT debruynephilipr geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT renardvincent geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT vromanphilippe geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT luytendaisy geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT nevenpatrick geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT amantfrederic geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT leunenkarin geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT vergoteignace geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer AT geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer |